{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:33:17Z","timestamp":1793395997776,"version":"4.5.0"},"reference-count":172,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ejmech.2026.118780","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T17:21:20Z","timestamp":1773854480000},"page":"118780","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Unlocking the potential of TNF: From biologic agents to small-molecule inhibitors"],"prefix":"10.1016","volume":"310","author":[{"given":"Yong","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanqing","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.118780_bib1","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1073\/pnas.72.9.3666","article-title":"An endotoxin-induced serum factor that causes necrosis of tumors","volume":"72","author":"Carswell","year":"1975","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2026.118780_bib2","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/312724a0","article-title":"Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin","volume":"312","author":"Pennica","year":"1984","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.118780_bib3","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1152\/physrev.00045.2017","article-title":"The TNF family of ligands and receptors: communication modules in the immune system and beyond","volume":"99","author":"Dostert","year":"2019","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.ejmech.2026.118780_bib4","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1038\/s42255-021-00470-z","article-title":"Metabolic messengers: tumour necrosis factor","volume":"3","author":"Sethi","year":"2021","journal-title":"Nat. Metab."},{"key":"10.1016\/j.ejmech.2026.118780_bib5","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nrrheum.2015.169","article-title":"TNF biology, pathogenic mechanisms and emerging therapeutic strategies","volume":"12","author":"Kalliolias","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.ejmech.2026.118780_bib6","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/s41584-023-01002-7","article-title":"TNF and TNF receptors as therapeutic targets for rheumatic diseases and beyond","volume":"19","author":"Siegmund","year":"2023","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.ejmech.2026.118780_bib7","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.cytogfr.2007.04.002","article-title":"How TNF was recognized as a key mechanism of disease","volume":"18","author":"Clark","year":"2007","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.ejmech.2026.118780_bib8","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.pharmthera.2007.10.001","article-title":"Tumor necrosis factor antagonist mechanisms of action: a comprehensive review","volume":"117","author":"Tracey","year":"2008","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2026.118780_bib9","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1007\/s40265-014-0258-9","article-title":"Etanercept: a review of its use in autoimmune inflammatory diseases","volume":"74","author":"Scott","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2026.118780_bib10","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nrm3742","article-title":"A day in the life of the spliceosome","volume":"15","author":"Matera","year":"2014","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2026.118780_bib11","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/s41573-024-01053-9","article-title":"Targeting the TNF and TNFR superfamilies in autoimmune disease and cancer","volume":"23","author":"Croft","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.118780_bib12","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S0092-8674(00)80367-0","article-title":"The spinal muscular atrophy disease gene product, SMN, and its associated protein SIP1 are in a complex with spliceosomal snRNP proteins","volume":"90","author":"Liu","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.118780_bib13","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S0092-8674(00)80368-2","article-title":"The SMN-SIP1 complex has an essential role in spliceosomal snRNP biogenesis","volume":"90","author":"Fischer","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.118780_bib14","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/nrd2654","article-title":"Certolizumab pegol","volume":"7","author":"Melmed","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.118780_bib15","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s40265-022-01821-0","article-title":"Ozoralizumab: first approval","volume":"83","author":"Keam","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2026.118780_bib16","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/nrrheum.2014.34","article-title":"Rheumatoid arthritis: when TNF inhibitors fail in RA--weighing up the options","volume":"10","author":"Silva-Fernandez","year":"2014","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.ejmech.2026.118780_bib17","doi-asserted-by":"crossref","DOI":"10.1038\/ctg.2015.63","article-title":"Loss of response to Anti-TNFs: definition, epidemiology, and management","volume":"7","author":"Roda","year":"2016","journal-title":"Clin. Transl. Gastroenterol."},{"key":"10.1016\/j.ejmech.2026.118780_bib18","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/bjd.12422","article-title":"Survival rate of antitumour necrosis factor-alpha treatments for psoriasis in routine dermatological practice: a multicentre observational study","volume":"169","author":"Esposito","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.ejmech.2026.118780_bib19","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0092-8674(88)90486-2","article-title":"A novel form of TNF\/Cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF","volume":"53","author":"Kriegler","year":"1988","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.118780_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26040944","article-title":"Strategies to target ADAM17 in disease: from its discovery to the iRhom revolution","volume":"26","author":"Calligaris","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2026.118780_bib21","first-page":"928","article-title":"iRHOM2 is a critical pathogenic mediator of inflammatory arthritis","volume":"123","author":"Issuree","year":"2013","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejmech.2026.118780_bib22","doi-asserted-by":"crossref","first-page":"17595","DOI":"10.1016\/S0021-9258(18)71533-0","article-title":"The structure of tumor necrosis factor-alpha at 2.6 A resolution. Implications for receptor binding","volume":"264","author":"Eck","year":"1989","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.118780_bib23","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0065-3233(08)60520-3","article-title":"The anatomy and taxonomy of protein structure","volume":"34","author":"Richardson","year":"1981","journal-title":"Adv. Protein Chem."},{"key":"10.1016\/j.ejmech.2026.118780_bib24","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/0092-8674(95)90192-2","article-title":"The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor","volume":"83","author":"Grell","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.118780_bib25","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1073\/pnas.95.2.570","article-title":"The type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor","volume":"95","author":"Grell","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2026.118780_bib26","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1093\/rheumatology\/keq031","article-title":"Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents","volume":"49","author":"Horiuchi","year":"2010","journal-title":"Rheumatology"},{"key":"10.1016\/j.ejmech.2026.118780_bib27","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1126\/science.288.5475.2351","article-title":"A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling","volume":"288","author":"Chan","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2026.118780_bib28","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/0092-8674(93)90132-A","article-title":"Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: implications for TNF receptor activation","volume":"73","author":"Banner","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.118780_bib29","doi-asserted-by":"crossref","first-page":"14617","DOI":"10.1074\/jbc.271.24.14617","article-title":"A novel cytoplasmic domain of the p55 tumor necrosis factor receptor initiates the neutral sphingomyelinase pathway","volume":"271","author":"Adam","year":"1996","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.118780_bib30","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/0092-8674(93)90464-2","article-title":"A novel domain within the 55 kd TNF receptor signals cell death","volume":"74","author":"Tartaglia","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.118780_bib31","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/j.1460-2075.1992.tb05133.x","article-title":"Cytoplasmic truncation of the p55 tumour necrosis factor (TNF) receptor abolishes signalling, but not induced shedding of the receptor","volume":"11","author":"Brakebusch","year":"1992","journal-title":"EMBO J."},{"key":"10.1016\/j.ejmech.2026.118780_bib32","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41577-022-00792-3","article-title":"Death by TNF: a road to inflammation","volume":"23","author":"van Loo","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ejmech.2026.118780_bib33","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aax5647","article-title":"Single-molecule imaging reveals the oligomeric state of functional TNFalpha-induced plasma membrane TNFR1 clusters in cells","volume":"13","author":"Karathanasis","year":"2020","journal-title":"Sci. Signal."},{"key":"10.1016\/j.ejmech.2026.118780_bib34","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/bioinformatics\/btaa844","article-title":"A systems-biology model of the tumor necrosis factor (TNF) interactions with TNF receptor 1 and 2","volume":"37","author":"Prada","year":"2021","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ejmech.2026.118780_bib35","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.it.2016.06.002","article-title":"More to life than NF-kappaB in TNFR1 signaling","volume":"37","author":"Ting","year":"2016","journal-title":"Trends Immunol."},{"key":"10.1016\/j.ejmech.2026.118780_bib36","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.tcb.2019.12.009","article-title":"RIPK1 kinase-dependent death: a symphony of phosphorylation events","volume":"30","author":"Delanghe","year":"2020","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.ejmech.2026.118780_bib37","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/sj.cdd.4401189","article-title":"Tumor necrosis factor signaling","volume":"10","author":"Wajant","year":"2003","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.ejmech.2026.118780_bib38","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3389\/fcell.2019.00091","article-title":"TNFR1 and TNFR2 in the control of the life and death balance of macrophages","volume":"7","author":"Wajant","year":"2019","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.ejmech.2026.118780_bib39","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1126\/science.1071924","article-title":"TNF-R1 signaling: a beautiful pathway","volume":"296","author":"Chen","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2026.118780_bib40","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1182\/blood-2011-04-325225","article-title":"Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey","volume":"119","author":"Aggarwal","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2026.118780_bib41","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/nri3834","article-title":"Regulation of tumour necrosis factor signalling: live or let die","volume":"15","author":"Brenner","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ejmech.2026.118780_bib42","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0092-8674(03)00521-X","article-title":"Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes","volume":"114","author":"Micheau","year":"2003","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.118780_bib43","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.cell.2008.03.036","article-title":"TNF-alpha induces two distinct caspase-8 activation pathways","volume":"133","author":"Wang","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.118780_bib44","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/nature14191","article-title":"Necroptosis and its role in inflammation","volume":"517","author":"Pasparakis","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.118780_bib45","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1056\/NEJMra1310050","article-title":"Necroptosis","volume":"370","author":"Linkermann","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.118780_bib46","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.cell.2011.11.031","article-title":"Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase","volume":"148","author":"Sun","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.118780_bib47","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nature13608","article-title":"RIPK1 maintains epithelial homeostasis by inhibiting apoptosis and necroptosis","volume":"513","author":"Dannappel","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.118780_bib48","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nature13706","article-title":"RIPK1 ensures intestinal homeostasis by protecting the epithelium against apoptosis","volume":"513","author":"Takahashi","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.118780_bib49","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.cytogfr.2020.03.002","article-title":"Selective inhibition of tumor necrosis factor receptor-1 (TNFR1) for the treatment of autoimmune diseases","volume":"55","author":"Zhang","year":"2020","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.ejmech.2026.118780_bib50","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1056\/NEJM200108023450506","article-title":"Autoimmune diseases","volume":"345","author":"Davidson","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.118780_bib51","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1219907","article-title":"TNF superfamily control of tissue remodeling and fibrosis","volume":"14","author":"Steele","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2026.118780_bib52","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1006\/phrs.1998.0463","article-title":"The role of TNF in cardiovascular disease","volume":"40","author":"Ferrari","year":"1999","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2026.118780_bib53","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/eji.201545798","article-title":"Transmembrane TNF-alpha is sufficient for articular inflammation and hypernociception in a mouse model of gout","volume":"46","author":"Amaral","year":"2016","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.ejmech.2026.118780_bib54","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22052719","article-title":"The role of tumor necrosis factor alpha (TNF-alpha) in autoimmune disease and current TNF-alpha inhibitors in therapeutics","volume":"22","author":"Jang","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.118780_bib55","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/hep.32738","article-title":"AIF1 + CSF1R + MSCs, induced by TNF-alpha, act to generate an inflammatory microenvironment and promote hepatocarcinogenesis","volume":"78","author":"Zong","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2026.118780_bib56","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1742-2094-7-27","article-title":"TNF-alpha and neuropathic pain--a review","volume":"7","author":"Leung","year":"2010","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.ejmech.2026.118780_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.exger.2023.112119","article-title":"The mechanisms and functions of TNF-alpha in intervertebral disc degeneration","volume":"174","author":"Pan","year":"2023","journal-title":"Exp. Gerontol."},{"key":"10.1016\/j.ejmech.2026.118780_bib58","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41584-021-00639-6","article-title":"Insights into the biology and therapeutic implications of TNF and regulatory T cells","volume":"17","author":"Salomon","year":"2021","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.ejmech.2026.118780_bib59","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.molmed.2022.12.001","article-title":"Dupuytren's disease: a localised and accessible human fibrotic disorder","volume":"29","author":"Layton","year":"2023","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.ejmech.2026.118780_bib60","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41572-020-0156-2","article-title":"Crohn's disease","volume":"6","author":"Roda","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.ejmech.2026.118780_bib61","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41572-020-0205-x","article-title":"Ulcerative colitis","volume":"6","author":"Kobayashi","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.ejmech.2026.118780_bib62","article-title":"Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis","author":"Burr","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.ejmech.2026.118780_bib63","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s10787-023-01221-0","article-title":"Rheumatoid arthritis","volume":"32","author":"Buchanan","year":"2024","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.ejmech.2026.118780_bib64","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/S0140-6736(07)60635-7","article-title":"Ankylosing spondylitis","volume":"369","author":"Braun","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2026.118780_bib65","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic arthritis","volume":"376","author":"Ritchlin","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.118780_bib66","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1016\/S0140-6736(18)30830-4","article-title":"The pathogenesis of psoriatic arthritis","volume":"391","author":"Veale","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2026.118780_bib67","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.ejmech.2026.118780_bib68","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1016\/S0140-6736(11)60244-4","article-title":"Juvenile idiopathic arthritis","volume":"377","author":"Prakken","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2026.118780_bib69","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","article-title":"A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's disease cA2 study Group","volume":"337","author":"Targan","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.118780_bib70","doi-asserted-by":"crossref","first-page":"13799","DOI":"10.1074\/jbc.M112.433961","article-title":"Structural basis for treating tumor necrosis factor alpha (TNFalpha)-associated diseases with the therapeutic antibody infliximab","volume":"288","author":"Liang","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.118780_bib71","unstructured":"Information on Tumor Necrosis Factor (TNF) Blockers (Marketed as Remicade, Enbrel, Humira, Cimzia, and Simponi)."},{"key":"10.1016\/j.ejmech.2026.118780_bib72","doi-asserted-by":"crossref","first-page":"27059","DOI":"10.1074\/jbc.M113.491530","article-title":"Comparison of the inhibition mechanisms of adalimumab and infliximab in treating tumor necrosis factor alpha-associated diseases from a molecular view","volume":"288","author":"Hu","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.118780_bib73","article-title":"Molecular basis for the neutralization of tumor necrosis factor alpha by certolizumab pegol in the treatment of inflammatory autoimmune diseases","volume":"18","author":"Lee","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.118780_bib74","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1002\/pro.3407","article-title":"Structural basis for tumor necrosis factor blockade with the therapeutic antibody golimumab","volume":"27","author":"Ono","year":"2018","journal-title":"Protein Sci."},{"key":"10.1016\/j.ejmech.2026.118780_bib75","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.ejmech.2026.118780_bib76","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007195","article-title":"Concurrent immune checkpoint inhibition and selective immunosuppressive therapy in patients with immune-related enterocolitis","volume":"11","author":"Badran","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ejmech.2026.118780_bib77","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1136\/ard-2023-223885","article-title":"Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis","volume":"82","author":"Bass","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ejmech.2026.118780_bib78","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41584-021-00584-4","article-title":"TNF in the era of immune checkpoint inhibitors: friend or foe?","volume":"17","author":"Chen","year":"2021","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.ejmech.2026.118780_bib79","article-title":"TNF-alpha inhibitors and other biologic agents for the treatment of immune checkpoint inhibitor-induced myocarditis","volume":"13","author":"Liu","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2026.118780_bib80","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/s13023-019-1201-7","article-title":"Update on the management of colchicine resistant familial Mediterranean Fever (FMF)","volume":"14","author":"El Hasbani","year":"2019","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ejmech.2026.118780_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2020.102421","article-title":"Systemic autoinflammatory diseases","volume":"109","author":"Krainer","year":"2020","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.ejmech.2026.118780_bib82","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jaci.2022.12.816","article-title":"Biologics and JAK inhibitors for the treatment of monogenic systemic autoinflammatory diseases in children","volume":"151","author":"Du","year":"2023","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.ejmech.2026.118780_bib83","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1091336","article-title":"Single-cell transcriptomic analysis in two patients with rare systemic autoinflammatory diseases treated with anti-TNF therapy","volume":"14","author":"Hua","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2026.118780_bib84","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/493593","article-title":"Anti-TNF-alpha therapy and systemic vasculitis","volume":"2014","author":"Jarrot","year":"2014","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.ejmech.2026.118780_bib85","first-page":"CD013818","article-title":"Tumor necrosis factor (TNF) inhibitors for juvenile idiopathic arthritis-associated uveitis","volume":"10","author":"Renton","year":"2022","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ejmech.2026.118780_bib86","doi-asserted-by":"crossref","DOI":"10.3892\/mmr.2021.12487","article-title":"Tumor necrosis factor inhibitors as therapeutic agents for recurrent spontaneous abortion","volume":"24","author":"Wu","year":"2021","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.ejmech.2026.118780_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109207","article-title":"Benefits of tumor necrosis factor inhibitors for cardiovascular disease in ankylosing spondylitis","volume":"112","author":"Huang","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.ejmech.2026.118780_bib88","doi-asserted-by":"crossref","first-page":"312","DOI":"10.3389\/fimmu.2020.00312","article-title":"Immunogenicity of TNF-Inhibitors","volume":"11","author":"Atiqi","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2026.118780_bib89","series-title":"Benzimidazles as TNF-alpha Modulators and their Preparation","author":"Brookings","year":"2013"},{"key":"10.1016\/j.ejmech.2026.118780_bib90","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41467-020-20825-6","article-title":"A conformation-selective monoclonal antibody against a small molecule-stabilised signalling-deficient form of TNF","volume":"12","author":"Lightwood","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.118780_bib91","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/s41467-020-20828-3","article-title":"Structural insights into the disruption of TNF-TNFR1 signalling by small molecules stabilising a distorted TNF","volume":"12","author":"McMillan","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.118780_bib92","doi-asserted-by":"crossref","first-page":"5795","DOI":"10.1038\/s41467-019-13616-1","article-title":"Small molecules that inhibit TNF signalling by stabilising an asymmetric form of the trimer","volume":"10","author":"O'Connell","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.118780_bib93","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1037983","article-title":"An orally available small molecule that targets soluble TNF to deliver anti-TNF biologic-like efficacy in rheumatoid arthritis","volume":"13","author":"Vugler","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.118780_bib94","doi-asserted-by":"crossref","first-page":"15050","DOI":"10.1021\/acs.jmedchem.0c01732","article-title":"Biologic-like in vivo efficacy with small molecule inhibitors of TNFalpha identified using scaffold hopping and structure-based drug design approaches","volume":"63","author":"Xiao","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118780_bib95","series-title":"Preparation of Heterocyclic Compounds Useful as TNF\u03b1 Modulators for Treatment of Inflammatory or Autoimmune Diseases","author":"Xiao","year":"2017"},{"key":"10.1016\/j.ejmech.2026.118780_bib96","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1021\/acs.jmedchem.0c01280","article-title":"Development of orally efficacious allosteric inhibitors of TNFalpha via fragment-based drug design","volume":"64","author":"Dietrich","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118780_bib97","series-title":"Potent ASGPR-binding Compounds for the Degradation of Immunoglobulins and Other Proteins","author":"Wiles","year":"2022"},{"key":"10.1016\/j.ejmech.2026.118780_bib98","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1126\/science.1116304","article-title":"Small-molecule inhibition of TNF-alpha","volume":"310","author":"He","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2026.118780_bib99","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1002\/ardp.201400198","article-title":"Rationally designed less toxic SPD-304 analogs and preliminary evaluation of their TNF inhibitory effects","volume":"347","author":"Alexiou","year":"2014","journal-title":"Arch Pharm (Weinheim)"},{"key":"10.1016\/j.ejmech.2026.118780_bib100","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1021\/tx700294g","article-title":"Metabolic activation of a novel 3-substituted indole-containing TNF-alpha inhibitor: dehydrogenation and inactivation of CYP3A4","volume":"21","author":"Sun","year":"2008","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.ejmech.2026.118780_bib101","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174285","article-title":"New contributions to the drug profile of TNFalpha inhibitor SPD304: affinity, selectivity and ADMET considerations","volume":"907","author":"Mascret","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.118780_bib102","doi-asserted-by":"crossref","first-page":"3424","DOI":"10.1038\/s41598-017-03427-z","article-title":"Identification of an in vivo orally active dual-binding protein-protein interaction inhibitor targeting TNFalpha through combined in silico\/in vitro\/in vivo screening","volume":"7","author":"Mouhsine","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2026.118780_bib103","doi-asserted-by":"crossref","first-page":"3511","DOI":"10.1021\/acs.jmedchem.6b01836","article-title":"Structural basis of small-molecule aggregate induced inhibition of a protein-protein interaction","volume":"60","author":"Blevitt","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118780_bib104","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/protein\/gzu055","article-title":"Subunit disassembly and inhibition of TNFalpha by a semi-synthetic bicyclic peptide","volume":"28","author":"Luzi","year":"2015","journal-title":"Protein Eng. Des. Sel."},{"key":"10.1016\/j.ejmech.2026.118780_bib105","doi-asserted-by":"crossref","first-page":"11879","DOI":"10.1073\/pnas.211178398","article-title":"Photochemically enhanced binding of small molecules to the tumor necrosis factor receptor-1 inhibits the binding of TNF-alpha","volume":"98","author":"Carter","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2026.118780_bib106","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1021\/acs.jcim.6b00672","article-title":"Discovery of novel ligands for TNF-alpha and TNF Receptor-1 through structure-based virtual screening and biological assay","volume":"57","author":"Chen","year":"2017","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2026.118780_bib107","doi-asserted-by":"crossref","first-page":"5359","DOI":"10.1007\/s00216-016-9633-6","article-title":"Identification of a ligand for tumor necrosis factor receptor from Chinese herbs by combination of surface plasmon resonance biosensor and UPLC-MS","volume":"408","author":"Cao","year":"2016","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.ejmech.2026.118780_bib108","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics10030100","article-title":"A simple and sensitive liquid chromatography with Tandem Mass spectrometric method for the simultaneous determination of anthraquinone glycosides and their aglycones in rat plasma: application to a pharmacokinetic study of Rumex acetosa extract","volume":"10","author":"Ullah","year":"2018","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejmech.2026.118780_bib109","article-title":"Pharmacokinetics, tissue distribution, and excretion characteristics of a Radix Polygoni multiflori extract in rats","volume":"13","author":"Cheng","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.118780_bib110","article-title":"Physcion and physcion 8-O-beta-glucopyranoside: a review of their pharmacology, toxicities and pharmacokinetics","volume":"310","author":"Xun","year":"2019","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.ejmech.2026.118780_bib111","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27238592","article-title":"A network-pharmacology-combined integrated pharmacokinetic strategy to investigate the mechanism of potential liver injury due to Polygonum multiflorum","volume":"27","author":"Jia","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2026.118780_bib112","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ejmech.2014.07.091","article-title":"Discovery of highly potent TNFalpha inhibitors using virtual screen","volume":"85","author":"Shen","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118780_bib113","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3389\/fchem.2018.00098","article-title":"Design, synthesis, and evaluation of Dihydrobenzo[cd]indole-6-sulfonamide as TNF-alpha inhibitors","volume":"6","author":"Deng","year":"2018","journal-title":"Front. Chem."},{"key":"10.1016\/j.ejmech.2026.118780_bib114","doi-asserted-by":"crossref","first-page":"8146","DOI":"10.1021\/acs.jmedchem.0c00377","article-title":"Discovery of an orally active small-molecule tumor necrosis factor-alpha inhibitor","volume":"63","author":"Sun","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118780_bib115","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.1021\/acs.jcim.2c01458","article-title":"Structure-based drug design and synthesis of Pyrrolidine-2,5-diones as novel TNF-alpha inhibitors","volume":"63","author":"Yang","year":"2023","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2026.118780_bib116","article-title":"A small molecule selected from a DNA-Encoded library of natural products that binds to TNF-alpha and attenuates inflammation in vivo","volume":"9","author":"Wang","year":"2022","journal-title":"Adv. Sci. (Weinh.)"},{"key":"10.1016\/j.ejmech.2026.118780_bib117","article-title":"Drug target identification using network analysis: taking active components in sini decoction as an example","volume":"6","author":"Chen","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2026.118780_bib118","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.chembiol.2009.09.011","article-title":"Discovery of TNF inhibitors from a DNA-encoded chemical library based on diels-alder cycloaddition","volume":"16","author":"Buller","year":"2009","journal-title":"Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.118780_bib119","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1039\/D0MD00208A","article-title":"Synthesis and biological screening of a library of macamides as TNF-alpha inhibitors","volume":"11","author":"Tena Perez","year":"2020","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118780_bib120","doi-asserted-by":"crossref","first-page":"9010","DOI":"10.1002\/anie.201202937","article-title":"A metal-based inhibitor of tumor necrosis factor-alpha","volume":"51","author":"Leung","year":"2012","journal-title":"Angew Chem. Int. Ed. Engl."},{"key":"10.1016\/j.ejmech.2026.118780_bib121","doi-asserted-by":"crossref","first-page":"4026","DOI":"10.1021\/acs.jmedchem.6b00112","article-title":"Identification of an Iridium(III)-Based inhibitor of tumor necrosis factor-alpha","volume":"59","author":"Kang","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118780_bib122","doi-asserted-by":"crossref","first-page":"405","DOI":"10.2203\/dose-response.11-052.Iavicoli","article-title":"Sub-chronic oral exposure to iridium (III) chloride hydrate in female wistar rats: distribution and excretion of the metal","volume":"10","author":"Iavicoli","year":"2012","journal-title":"Dose Response"},{"key":"10.1016\/j.ejmech.2026.118780_bib123","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/0192-0561(92)90125-5","article-title":"Inhibitory effect of suramin on receptor binding and cytotoxic activity of tumor necrosis factor alpha","volume":"14","author":"Grazioli","year":"1992","journal-title":"Int. J. Immunopharm."},{"key":"10.1016\/j.ejmech.2026.118780_bib124","doi-asserted-by":"crossref","first-page":"12526","DOI":"10.1016\/S0021-9258(18)31420-0","article-title":"Suramin induces deoligomerization of human tumor necrosis factor alpha","volume":"268","author":"Alzani","year":"1993","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.118780_bib125","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.2174\/138955708786369573","article-title":"Suramin: clinical uses and structure-activity relationships","volume":"8","author":"McGeary","year":"2008","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118780_bib126","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S0006-2952(99)00150-1","article-title":"Inhibition of tumor necrosis factor-alpha (TNF-alpha)\/TNF-alpha receptor binding by structural analogues of suramin","volume":"58","author":"Mancini","year":"1999","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.118780_bib127","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1517\/13543784.13.10.1361","article-title":"Suramin: potential in acute liver failure","volume":"13","author":"Doggrell","year":"2004","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.ejmech.2026.118780_bib128","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1038\/nbt1197-1266","article-title":"Structure-based design and characterization of exocyclic peptidomimetics that inhibit TNF alpha binding to its receptor","volume":"15","author":"Takasaki","year":"1997","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ejmech.2026.118780_bib129","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1002\/art.22495","article-title":"A tumor necrosis factor receptor loop peptide mimic inhibits bone destruction to the same extent as anti-tumor necrosis factor monoclonal antibody in murine collagen-induced arthritis","volume":"56","author":"Saito","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ejmech.2026.118780_bib130","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25040922","article-title":"Structure-based design, synthesis and bioactivity of a new Anti-TNFalpha cyclopeptide","volume":"25","author":"Idress","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2026.118780_bib131","doi-asserted-by":"crossref","first-page":"11990","DOI":"10.1021\/ja405106u","article-title":"Screening bicyclic peptide libraries for protein-protein interaction inhibitors: discovery of a tumor necrosis factor-alpha antagonist","volume":"135","author":"Lian","year":"2013","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2026.118780_bib132","doi-asserted-by":"crossref","first-page":"12457","DOI":"10.1074\/jbc.M113.521708","article-title":"A novel small-molecule tumor necrosis factor alpha inhibitor attenuates inflammation in a hepatitis mouse model","volume":"289","author":"Ma","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.118780_bib133","series-title":"The Application of C87, a Small Molecule Inhibitor of TNF \u03b1, in the Preparation of Glioma Drugs","author":"Xu","year":"2019"},{"key":"10.1016\/j.ejmech.2026.118780_bib134","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1021\/jm1013693","article-title":"Synopsis of some recent tactical application of bioisosteres in drug design","volume":"54","author":"Meanwell","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118780_bib135","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.addr.2007.05.013","article-title":"Prodrug strategies to overcome poor water solubility","volume":"59","author":"Stella","year":"2007","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejmech.2026.118780_bib136","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nrd.2018.46","article-title":"The expanding role of prodrugs in contemporary drug design and development","volume":"17","author":"Rautio","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.118780_bib137","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1005372","article-title":"Cheminformatics-aided discovery of small-molecule protein-protein interaction (PPI) dual inhibitors of tumor necrosis factor (TNF) and receptor activator of NF-kappaB ligand (RANKL)","volume":"13","author":"Melagraki","year":"2017","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.ejmech.2026.118780_bib138","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.abi8713","article-title":"An orally active, small-molecule TNF inhibitor that disrupts the homotrimerization interface improves inflammatory arthritis in mice","volume":"15","author":"Javaid","year":"2022","journal-title":"Sci. Signal."},{"key":"10.1016\/j.ejmech.2026.118780_bib139","doi-asserted-by":"crossref","first-page":"5010","DOI":"10.1039\/c1cc10715a","article-title":"A new three-component reaction: green synthesis of novel isoindolo[2,1-a]quinazoline derivatives as potent inhibitors of TNF-alpha","volume":"47","author":"Kumar","year":"2011","journal-title":"Chem. Commun."},{"key":"10.1016\/j.ejmech.2026.118780_bib140","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1016\/j.bmcl.2014.04.115","article-title":"Synthesis and structure-activity relationship of cyclopentenone oximes as novel inhibitors of the production of tumor necrosis factor-alpha","volume":"24","author":"Kim","year":"2014","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.118780_bib141","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.bcp.2010.12.020","article-title":"The food colorant erythrosine is a promiscuous protein-protein interaction inhibitor","volume":"81","author":"Ganesan","year":"2011","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.118780_bib142","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.canlet.2010.05.016","article-title":"A small oxazine compound as an anti-tumor agent: a novel pyranoside mimetic that binds to VEGF, HB-EGF, and TNF-alpha","volume":"297","author":"Basappa","year":"2010","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejmech.2026.118780_bib143","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jconrel.2012.01.043","article-title":"PLGA-based nanoparticles: an overview of biomedical applications","volume":"161","author":"Danhier","year":"2012","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.ejmech.2026.118780_bib144","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.addr.2012.09.037","article-title":"Liposomal drug delivery systems: from concept to clinical applications","volume":"65","author":"Allen","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejmech.2026.118780_bib145","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/nrd3701","article-title":"Finding the sweet spot: the role of nature and nurture in medicinal chemistry","volume":"11","author":"Hann","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.118780_bib146","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejmech.2026.118780_bib147","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/cmdc.201100016","article-title":"Structure-based repurposing of FDA-Approved drugs as TNF-Alpha inhibitors","volume":"6","author":"Leung","year":"2011","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2026.118780_bib148","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.ejmech.2013.10.032","article-title":"Synthesis of novel 1,2,3-triazole based benzoxazolinones: their TNF-alpha based molecular docking with in-vivo anti-inflammatory, antinociceptive activities and ulcerogenic risk evaluation","volume":"70","author":"Haider","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118780_bib149","doi-asserted-by":"crossref","first-page":"6195","DOI":"10.1016\/j.bmcl.2010.08.116","article-title":"Discovery of the inhibitors of tumor necrosis factor alpha with structure-based virtual screening","volume":"20","author":"Choi","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.118780_bib150","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1021\/ci700286x","article-title":"Natural product-likeness score and its application for prioritization of compound libraries","volume":"48","author":"Ertl","year":"2008","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2026.118780_bib151","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1002\/1521-3773(20020816)41:16<2878::AID-ANIE2878>3.0.CO;2-B","article-title":"From protein domains to drug candidates-natural products as guiding principles in the design and synthesis of compound libraries","volume":"41","author":"Breinbauer","year":"2002","journal-title":"Angew Chem. Int. Ed. Engl."},{"key":"10.1016\/j.ejmech.2026.118780_bib152","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1021\/np068054v","article-title":"Natural products as sources of new drugs over the last 25 years","volume":"70","author":"Newman","year":"2007","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.ejmech.2026.118780_bib153","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1002\/anie.200907360","article-title":"Structure-based discovery of natural-product-like TNF-alpha inhibitors","volume":"49","author":"Chan","year":"2010","journal-title":"Angew Chem. Int. Ed. Engl."},{"key":"10.1016\/j.ejmech.2026.118780_bib154","doi-asserted-by":"crossref","first-page":"31879","DOI":"10.1074\/jbc.M114.593855","article-title":"Novel synthetic biscoumarins target tumor necrosis factor-alpha in hepatocellular carcinoma in vitro and in vivo","volume":"289","author":"Keerthy","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.118780_bib155","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1016\/j.bcp.2012.08.025","article-title":"Japonicone A antagonizes the activity of TNF-alpha by directly targeting this cytokine and selectively disrupting its interaction with TNF receptor-1","volume":"84","author":"Hu","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.118780_bib156","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.bmcl.2008.12.043","article-title":"Japonicones A-D, bioactive dimeric sesquiterpenes from Inula japonica Thunb","volume":"19","author":"Qin","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.118780_bib157","doi-asserted-by":"crossref","first-page":"800","DOI":"10.3389\/fphar.2018.00800","article-title":"In silico discovery of plant-origin natural product inhibitors of tumor necrosis factor (TNF) and receptor activator of NF-kappaB ligand (RANKL)","volume":"9","author":"Melagraki","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.118780_bib158","doi-asserted-by":"crossref","DOI":"10.3390\/ijms221910220","article-title":"In silico identification and evaluation of natural products as potential tumor necrosis factor function inhibitors using advanced enalos asclepios KNIME nodes","volume":"22","author":"Papadopoulou","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.118780_bib159","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9091250","article-title":"A novel competitive binding screening assay reveals sennoside B as a potent natural product inhibitor of TNF-alpha","volume":"9","author":"Peng","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.ejmech.2026.118780_bib160","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2019.112938","article-title":"Pharmacokinetic and metabolic profiling studies of sennoside B by UPLC-MS\/MS and UPLC-Q-TOF-MS","volume":"179","author":"Wu","year":"2020","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.ejmech.2026.118780_bib161","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1039\/b902041a","article-title":"Saponins as novel TNF-alpha inhibitors: isolation of saponins and a nor-pseudoguaianolide from Parthenium hysterophorus","volume":"7","author":"Shah","year":"2009","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.ejmech.2026.118780_bib162","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1021\/np50115a023","article-title":"Anti-inflammatory activity of saikosaponins from Heteromorpha trifoliata","volume":"58","author":"Recio","year":"1995","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.ejmech.2026.118780_bib163","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.123227","article-title":"Diclofenac prodrugs nanoparticles: an alternative and efficient treatment for rheumatoid arthritis?","volume":"643","author":"Hussain","year":"2023","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejmech.2026.118780_bib164","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/cpt.3655","article-title":"First-in-Human single and multiple ascending dose studies of balinatunfib, a small molecule inhibitor of TNFR1 signaling in healthy participants","volume":"118","author":"Nassr","year":"2025","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2026.118780_bib165","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.121213","article-title":"Stability, pharmacokinetics, and biodistribution in mice of the EPAC1 inhibitor (R)-CE3F4 entrapped in liposomes and lipid nanocapsules","volume":"610","author":"Toussaint","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejmech.2026.118780_bib166","first-page":"A335","article-title":"IDDF2025-ABS-0208 dual targeted therapy for refractory inflammatory bowel disease: a systematic review and meta-analysis","volume":"74","author":"Xu","year":"2025","journal-title":"Gut"},{"key":"10.1016\/j.ejmech.2026.118780_bib167","article-title":"Combination therapy with TNF inhibitors plus biologics targeting type 2 inflammatory conditions in patients with rheumatoid arthritis: a case series","volume":"10","author":"Ocon","year":"2026","journal-title":"Rheumatol Adv Pract"},{"issue":"9","key":"10.1016\/j.ejmech.2026.118780_bib168","article-title":"Breaking inflammatory pathways: ELN28, a novel dual TNF\u03b1\/JAK inhibitor drug conjugate for chronic inflammation","volume":"77","author":"Ubah O","year":"2025","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.ejmech.2026.118780_bib169","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1001\/jamadermatol.2025.2714","article-title":"Biopharmaceutical switching in psoriasis treatment: a systematic review and meta-analysis","volume":"161","author":"Zhang","year":"2025","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.ejmech.2026.118780_bib170","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1007\/s00216-008-1938-7","article-title":"Off-target activity of TNF-alpha inhibitors characterized by protein biochips","volume":"391","author":"Feyen","year":"2008","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.ejmech.2026.118780_bib171","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s00204-025-04226-6","article-title":"A broad kinase inhibitor library live cell imaging screen using liver, kidney and cardiac hiPSC-ICAM1-eGFP reporter lineages identifies liabilities for TNFalpha pathway modulation","volume":"100","author":"Vlasveld","year":"2026","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.ejmech.2026.118780_bib172","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ard.2025.05.409","article-title":"POS0012 selective inhibition of TNFR1 signal by balinatunfib in vitro does not inhibit treg expansion in contrast to anti-TNF biologics inhibiting TNFR1 and TNFR2 signaling","volume":"84","author":"Sibenhorn","year":"2025","journal-title":"Ann. Rheum. Dis."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426002254?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426002254?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T22:46:18Z","timestamp":1776120378000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426002254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":172,"alternative-id":["S0223523426002254"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118780","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unlocking the potential of TNF: From biologic agents to small-molecule inhibitors","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118780","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118780"}}